$543 Million is the total value of Darwin Global Management, Ltd.'s 12 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 83.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XLRN | Buy | ACCELERON PHARMA INC | $344,200,000 | +55.8% | 2,000,000 | +13.6% | 63.36% | +77.8% |
| NTLA | Sell | INTELLIA THERAPEUTICS INC | $100,884,000 | -66.5% | 752,024 | -59.6% | 18.57% | -61.8% |
| BNTX | New | BIONTECH SEsponsored ads | $36,289,000 | – | 132,932 | +100.0% | 6.68% | – |
| FATE | Buy | FATE THERAPEUTICS INC | $20,937,000 | -28.2% | 353,250 | +5.2% | 3.85% | -18.1% |
| INBX | Buy | INHIBRX INC | $18,074,000 | +191.3% | 542,586 | +140.6% | 3.33% | +232.4% |
| BBIO | Sell | BRIDGEBIO PHARMA INC | $11,891,000 | -42.1% | 253,692 | -24.7% | 2.19% | -33.9% |
| New | ADAGIO THERAPEUTICS INC | $3,655,000 | – | 86,528 | +100.0% | 0.67% | – | |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $2,869,000 | -34.6% | 159,393 | -36.2% | 0.53% | -25.4% |
| VIR | New | VIR BIOTECHNOLOGY INC | $1,972,000 | – | 45,311 | +100.0% | 0.36% | – |
| VERV | Sell | VERVE THERAPEUTICS INC | $1,288,000 | -79.2% | 27,397 | -73.4% | 0.24% | -76.3% |
| FULC | New | FULCRUM THERAPEUTICS INC | $959,000 | – | 33,997 | +100.0% | 0.18% | – |
| AVTE | New | AEROVATE THERAPEUTICS INC | $262,000 | – | 12,484 | +100.0% | 0.05% | – |
| GBIO | Exit | GENERATION BIO CO | $0 | – | -10,738 | -100.0% | -0.05% | – |
| RLAY | Exit | RELAY THERAPEUTICS INC | $0 | – | -119,775 | -100.0% | -0.71% | – |
| KROS | Exit | KEROS THERAPEUTICS INC | $0 | – | -104,186 | -100.0% | -0.71% | – |
| EPIX | Exit | ESSA PHARMA INC | $0 | – | -208,524 | -100.0% | -0.96% | – |
| BEAM | Exit | BEAM THERAPEUTICS INC | $0 | – | -126,985 | -100.0% | -2.64% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| FATE THERAPEUTICS INC | 5 | Q4 2021 | 24.2% |
| KEROS THERAPEUTICS INC | 5 | Q1 2023 | 12.8% |
| INHIBRX INC | 5 | Q4 2021 | 3.9% |
| ACCELERON PHARMA INC | 4 | Q3 2021 | 63.4% |
| AMBRX BIOPHARMA INC | 4 | Q3 2023 | 67.5% |
| ARGENX SE | 4 | Q3 2023 | 70.2% |
| BRIDGEBIO PHARMA INC | 4 | Q3 2021 | 25.2% |
| FULCRUM THERAPEUTICS INC | 4 | Q4 2021 | 0.9% |
| ASTRAZENECA PLC | 3 | Q2 2022 | 100.0% |
| INTELLIA THERAPEUTICS INC | 3 | Q4 2021 | 48.6% |
View Darwin Global Management, Ltd.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-28 |
| SC 13D/A | 2023-06-28 |
| SC 13D/A | 2023-05-25 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-04-03 |
| 3 | 2023-03-08 |
View Darwin Global Management, Ltd.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.